Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo, and Active Comparator-controlled, Parallel-group Study of the Efficacy and Safety of Rivoglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus

NCT00571519 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT00571519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00571519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo, and Active Comparator-controlled, Parallel-group Study of the Efficacy and Safety of Rivoglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus
Lead sponsor
Daiichi Sankyo
Phase
Phase 3
Overall status
Terminated
Start date
November 14, 2007
Completion date
May 23, 2008
Enrollment
94 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus